Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S021 - Dilemmas and Challenges in Skin Cancer Therapies and Management

Saturday, February 17; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Apply new results from research and the literature to their clinical practice setting to benefits their patients.
  • Integrate new concepts into clinical practice related to skin cancer on a regular basis.

Description

Therapeutic and management Issues related to skin cancer are dealt with on a daily basis by Dermatologists and lack of a comprehensive therapeutic and management issues can lead to increased morbidity and mortality. This course will be designed to related present key factors that impact on patient care and how to apply current therapies and management approaches. Spirited Questions and Answers with active audience participation will be encouraged. This symposium will work toward delivering practical therapeutic and management solutions to these issues that can be immediately incorporated into the attendee’s patient care setting. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Bhatia, Neal D., MD: AbbVie – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); Allergan, Inc – C(H); Almirall – C(H); Asana Biosciences, LLC – I(Grants/Research Funding); Atacama Therapeutics – I(Grants/Research Funding); Biofrontera AG – C(H); BioPharmX – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Crown Laboratories, Inc. – I(Grants/Research Funding); Cutanea Life Sciences – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H); Glenmark Generics Inc. – I(Grants/Research Funding); IntraDerm Pharmaceuticals – C(H); ISDIN – C(H); La Roche-Posay Laboratorie Pharmaceutique – C(H); LEO Pharma, US – I(Grants/Research Funding); Mayne Pharma Group – C(H); MC2 Therapeutics – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H); Ortho Dermatologics – C(H); Par Pharmaceutical – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – C(H); Promius Pharma, LLC – A(H); Realm Therapeutics – I(Grants/Research Funding); Sanofi/Regeneron – C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Skinfix, Inc. – A(H); Sol-Gel Technologies – I(Grants/Research Funding); Soligenix, Inc – I(Grants/Research Funding); Strata Skin Sciences – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals International – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Ceilley, Roger I., MD: Biofrontera AG – A(H); Ferndale Laboratories, Inc. – A(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – A(H);
  • Curiel-Lewandrowski, Clara N., MD: Amendia – C(H); Amgen – C(H);
  • Desai, Seemal R., MD: AbbVie – C(Fees), I(Grants/Research Funding); Allergan, Inc – C(Fees); Cassiopea SpA – C(H); Dermira – I(Grants/Research Funding); Dr. Reddy – I(Grants/Research Funding); Ferndale Laboratories, Inc. – A(Fees); Galderma Laboratories, LP – C(Fees); Menlo Therapeutics – C(H), I(Grants/Research Funding); Or-Genix, Therapeutics – C(H); Ortho Dermatologics – C(H), SP(H); Pfizer Inc. – SP(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); SkinCeuticals LLC – C(H); Symbio – I(Grants/Research Funding);
  • Grant-Kels, Jane Margaret, MD: no financial relationships exist with commercial interests.
  • High, Whitney A., MD, JD: no financial relationships exist with commercial interests.
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Aqua – C(H); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Boehringer Ingelheim – C(H); Bristol-Myers Squibb – C(H); Celgene Corporation – I(Grants/Research Funding); Corrona, Inc. – O(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding); Vidac Pharma – I(Grants/Research Funding);
  • Lim, Henry W., MD: Estee Lauder – I(Grants/Research Funding); Ferndale Laboratories, Inc. – I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); unigen – I(Grants/Research Funding);
  • Lushniak, Boris D., MD: no financial relationships exist with commercial interests.
  • Nouri, Keyvan, MD: no financial relationships exist with commercial interests.
  • Rigel, Darrell S., MD: Aclaris Therapeutics, Inc. – C(H); Beiersdorf, Inc. – A(H); Castle Biosciences – A(H), I(Grants/Research Funding); Derm Tech International – A(H); Foamix – B(H); Johnson and Johnson Consumer Products Company – I(H); LEO Pharma, US – A(H); Myriad Genetics Inc – A(H); Neutrogena Corporation – I(H); Novartis – A(H); Pierre Fabre Dermo-Cosmétique US – A(H); Valeant Pharmaceuticals International – A(H);
  • Swetter, Susan M., MD: no financial relationships exist with commercial interests.
Schedule
Saturday, February 17
9:00 AM
Dr. Rigel / Introduction: Why the issue is Important
9:05 AM
Dr. Grant-Kels / Skin Cancer in the Pediatric Population
9:18 AM
Dr. Lushniak / Can Public Health make an impact on Indoor Tanning
9:31 AM
Dr. Bhatia / Non-Surgical Approaches for BCCs – New Advances
9:44 AM
Dr. Lim / Does Photoprotection lower skin cancer risk?
9:57 AM
Dr. Ceilley / Field vs Lesional Therapies for AKs – When to use Which?
10:10 AM
Dr. Lebwohl / Do Psoriasis therapies increase skin cancer risk?
10:23 AM
Dr. Grant-Kels, Dr. Bhatia, Dr. Lim, Dr. Lebwohl, Dr. Lushniak, and Dr. Ceilley / Faculty Q&A
10:30 AM
Dr. Rigel / Do Primary and Secondary Melanoma prevention efforts make a difference?
10:43 AM
Dr. Curiel-Lewandrowski / Does Serial Imaging Play a Role in Melanoma Management?
10:56 AM
Dr. Swetter / What You Need to Know about Advanced MM Therapies – Targeted Approaches
11:09 AM
Dr. Desai / Skin Cancer Issues in Skin of Color
11:22 AM
Dr. High / Integrating genetics into the diagnosis and management of Melanoma
11:35 AM
Dr. Nouri / Current Guidelines for Surgical Management of MM – Margin and SLNBx Recommendations
11:48 AM
Dr. Rigel, Dr. Desai, Dr. Curiel-Lewandrowski, Dr. Swetter, Dr. High, and Dr. Nouri / Faculty Q&A
Event Details
  • Date
    Saturday, February 17
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 5A
  • CME Credits
    3.00
  • Type
    MOC
Directors/Co-Directors
Speakers
  • Boris D. Lushniak, MD, FAAD
  • Clara N. Curiel-Lewandrowski, MD, FAAD
  • Henry W. Lim, MD, FAAD - Handout
  • Jane Margaret Grant-Kels, MD, FAAD - Handout
  • Keyvan Nouri, MD, FAAD - Handout
  • Mark Lebwohl, MD, FAAD - Handout
  • Neal D. Bhatia, MD, FAAD - Handout
  • Roger I. Ceilley, MD, FAAD - Handout
  • Seemal R. Desai, MD, FAAD
  • Susan M. Swetter, MD, FAAD - Handout
  • Whitney A. High, MD, JD, FAAD